15 Results for "

Advanced Solid Malignancy

" in MedChemExpress (MCE) Product Catalog:
Products (15)

15 Results for "Advanced Solid Malignancy" in MCE Product Catalog:

7
7 Publications Verification
Cat. No.: HY-136173
CAS No.: 1801765-04-7
Purity:  99.41%
Synonyms: TNO155
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

Batoprotafib (TNO155) is a potent selective and orally active allosteric inhibitor of wild-type SHP2 (IC50=0.011 µM). Batoprotafib has the potential for the study of RTK-dependent malignancies, especially advanced solid tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145804
CAS No.: 2756333-39-6
Purity:  98.54%
Synonyms: AZD-9574
Target:  

PPAR

Research Areas:  

Neurological Disease Cancer

AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD +?breast cancer and advanced solid malignancies research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99364
CAS No.: 1024603-92-6
Synonyms: Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1

Target:  

VEGFR Apoptosis p38 MAPK Akt

Research Areas:  

Endocrinology Cancer

Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is an IgG1 antibody inhibitor targeting VEGFR-1/FLT1 with anti-tumor activity. By blocking ligand-dependent phosphorylation and downstream signal transduction, Icrucumab reduces the activities of MAPK and Akt in breast cancer xenograft models, inhibits the proliferation and invasion of VEGFR-1-positive tumor cells, and reverses the conversion of M1 macrophages to the pro-tumor M2-like phenotype. Icrucumab also inhibits tumor cell proliferation, promotes apoptosis, and effectively suppresses tumor growth through direct targeting of tumors and host support mechanisms. In addition, Icrucumab exhibits a synergistic effect when combined with chemotherapeutic agents, and it is used in research related to various cancers including advanced solid malignancies, thyroid cancer, melanoma, and lung cancer .
loading...
    loading...
Cat. No.: HY-16496
CAS No.: 26599-17-7
Synonyms: OSI-7836
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...
Cat. No.: HY-P990033
CAS No.: 2543693-10-1
Synonyms: CC-95251; BMS-986351

Target:  

CD47

Research Areas:  

Cancer

Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .
loading...
    loading...
Cat. No.: HY-P991180

Target:  

TNF Receptor

Research Areas:  

Cancer

TRX-518 is a humanized agylcosyl IgG1 anti-GITR mAb, , and is a GITR agonist. TRX-518 binds to the extracellular domain of human GITR, abrogates Treg-mediated suppression. TRX-518 increases effector T cell activation and pro-inflammatory cytokine production, reduces circulating and intratumor Treg frequencies. TRX-518 destabilizes Treg phenotype via Foxp3 downregulation and T-bet upregulation. TRX-518 can be used for the research of solid tumors[1][2][3].
loading...
    loading...
Cat. No.: HY-P99475
CAS No.: 2460539-60-8
Synonyms: MSB-2311

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Betifisolimab (MSB-2311) is a humanized monoclonal antibody directed against the immunosuppressive ligand PD-L1. Betifisolimab has the potential for advanced solid tumors and hematological malignancies research .
loading...
    loading...
Cat. No.: HY-P99027
CAS No.: 2137049-37-5
Synonyms: LAG525; IMP701; Hu5A8

Target:  

LAG-3

Research Areas:  

Cancer

Ieramilimab (LAG525; IMP701) is a humanized IgG4 monoclonal antibody that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules. Ieramilimab restores T-cell and NK-cell-mediated antileukemic immunity by reducing exhaustion and augmenting cytokine output and cytotoxicity. Ieramilimab increases the infiltration of cytotoxic T lymphocytes and reduces baseline densities of regulatory T cells (Tregs) and ADAM10-expressing tumor cells. Ieramilimab can be used for the study of various malignancies including melanoma, RCC, and advanced solid tumors .
loading...
    loading...
Cat. No.: HY-P991612
Synonyms: Sym024

Target:  

CD73

Research Areas:  

Inflammation/Immunology Cancer

S095024 is a humanized IgG1 monoclonal antibody inhibitor targeting CD73. S095024 can be used to study acute respiratory distress syndrome (ARDS), non-small cell lung cancer (NSCLC) and advanced solid tumor malignancies .
loading...
    loading...
Cat. No.: HY-P99911
CAS No.: 1635395-27-5
Synonyms: MEDI-6383
Efizonerimod alfa (MEDI-6383) is a recombinant human OX40L IgG4P Fc fusion protein that assembles into a hexameric structure and exerts potent agonist activity upon binding to OX40. The activity of Efizonerimod alfa is enhanced by Fcγ receptor-mediated aggregation. Efizonerimod alfa binds to OX40 on the surface of activated T cells, induces NF-κB promoter activity in OX40-expressing T cells, and triggers the production of Th1-type cytokines, T cell proliferation, and resistance to regulatory T cell (Treg)-mediated suppression. Efizonerimod alfa enhances the cytolytic activity of tumor-reactive T cells and slows tumor growth in immunodeficient mice. Efizonerimod alfa induces the proliferation of CD4, CD8, and B cells in the peripheral blood of healthy non-human primates. Efizonerimod alfa can be used in the research of advanced solid malignancies and melanoma .
loading...
    loading...
Cat. No.: HY-183774
CAS No.: 2750027-59-7
Target:  

TAM Receptor

Research Areas:  

Cancer

NTQ2494 is a potent and orally active AXL kinase inhibitor with an IC50 of 4.89 nM. NTQ2494 inhibits AXL kinase catalytic activity. NTQ2494 suppresses tumor growth in mouse xenograft models. NTQ2494 can be used for the research of advanced hematological malignancies, solid tumors .
loading...
    loading...
Cat. No.: HY-184499
CAS No.: 2420554-24-9
Target:  

MHC Aminopeptidase

Research Areas:  

Cancer

GRWD5769 is an orally potent ERAP1 inhibitor. GRWD5769 regulates the peptide repertoire presented by MHC-I, alters TCR diversity/clonality, reprograms antigen-experienced T cells, induces novel T cell responses, drives tumor cell killing, and alleviates T cell exhaustion. GRWD5769 can be used in the research of advanced solid malignancies, microsatellite-stable colorectal cancer, non-small cell lung cancer, bladder cancer, hepatocellular carcinoma, head and neck squamous cell carcinoma, and cervical cancer .
loading...
    loading...
Cat. No.: HY-16496A
CAS No.: 1060763-87-2
Synonyms: OSI-7836 hydrochloride
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Thiarabine (OSI-7836) hydrochloride is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine hydrochloride is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine hydrochloride is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies .
loading...
    loading...
Cat. No.: HY-P992450

Target:  

TNF Receptor

Research Areas:  

Cancer

REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001 .
loading...
    loading...
Cat. No.: HY-P992002

Target:  

ADC Antibodies

Research Areas:  

Cancer

AMT-151 Antibody is a monoclonal antibody inhibitor targeting folate receptor α. AMT-151 Antibody can be used to synthesize the antibody-drug conjugate (ADC) AMT-151. AMT-151 Antibody can be used to research related to cancer .
loading...
    loading...
  • 1